Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Join | Sign in
Home>News>This Article
  News
Return

PsiOxus to Release Study Results of Oncolytic Vaccine Enadenotucirev

Published: Saturday, May 17, 2014
Last Updated: Saturday, May 17, 2014
Bookmark and Share
Phase I studies to be presented at 2014 ASCO annual meeting.


Access to this article and other content is for registered users.

Join the Technology Networks Community

  • Access to the latest scientific news, products and research through Technology Networks
  • Upload and share your posters on ePosters
  • View a library of 1,800+ scientific and medical posters
  • A library of 3,000+ scientific videos on LabTube


Sign In



Forgotten your details? Click Here
If you already have an account with Technology Networks, please use your existing login details. If you do not yet have an account please join here.

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Protein That Boosts Immunity To Viruses And Cancer Discovered
Scientists have discovered a protein that plays a central role in promoting immunity to viruses and cancer, opening the door to new therapies.
NMR ‘Fingerprinting’ for Monoclonal Antibodies
Study by NIST researchers shows the use of NMR spectroscopy for measuring the structural congfiguration of monoclonal antibodies.
Promising Developments In Tackling Resistance To Blood Cancer Drugs
A new drug with the potential to reverse resistance to immunotherapy has been developed by scientists at the University of Southampton.
Recruiting The Entire Immune System To Attack Cancer
Stimulating both major branches of the immune system halts tumor growth more effectively.
New Antibody Therapy Shows Promise in Suppressing HIV Infection
New study finds that administration of 3BNC117 can catch HIV off guard and reduce viral loads.
Personalized Melanoma Vaccines Marshal Powerful Immune Response
Vaccines target unique mutations in each patient’s tumor.
Experimental Ebola Vaccine Safe, Prompts Immune Response
Results from US government-sponsored phase 1 trial of VSV vaccine reported.
Ebola Test Vaccines Appear Safe in Phase 2 Liberian Clinical Trial
Liberia-U.S. partnership planning Phase 3 trial and study of Ebola survivors.
Study Announces a Durable Vaccine for Ebola
Researchers from Plymouth University have led team which has developed a durable vaccine for Ebola together with a disseminating vaccine strategy.
New Hopes For Rheumatic Fever Vaccination
Progress is made by a new initiative funded by CANVAS.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters